Lenacapavir

Justicia Shipena  The director-general of the World Health Organisation (WHO), Tedros Ghebreyesus, has endorsed new WHO guidelines recommending long-acting injectable lenacapavir for HIV prevention.  He described it as a critical step in expanding access to a powerful tool that could prevent most HIV infections among at-risk populations.  Lenacapavir, developed by Gilead Sciences, is a long‑acting antiretroviral for HIV prevention and treatment. “While an HIV vaccine remains elusive, lenacapavir is the next best thing,” Dr Tedros said in a statement.  He said WHO is committed to working with countries and partners to ensure this innovation reaches communities as quickly and safely as…